Answers are grounded in this paper and cite their sources.
Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. MCL patients typically live for years but experience multiple relapses. Acalabrutinib is a novel second-generation oral Bruton tyrosine kinase inhibitor approved by the US Food and Drug Administration for relapsed MCL based on a clinical trial demonstrating an overall response rate of 81%. It provides a valuable new treatment option for MCL patients and is now being tested upfront.
No takes yet. Share an insight, caveat, or question.
Witzig et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: